Ozempic Improves Glycemic Control, Cuts Weight in Schizophrenia Patients

https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
(MedPage Today) — Low-dose semaglutide (Ozempic, Wegovy) improved glycemic control and weight outcomes in a randomized trial of adults whose schizophrenia was treated with the second-generation antipsychotics clozapine or olanzapine. THE…




